ANGLE’s Parsortix demonstrates potential to out-perform current standards for prostate cancer detection

The biotech said the Parsortix test could prevent a “substantial proportion” of unnecessary biopsies in patients being tested for the cancer

ANGLE PLC - ANGLE’s Parsortix demonstrates potential to out-perform current standards for prostate cancer detection
There are around 47,700 new prostate cancer cases in the UK each year

ANGLE PLC’s (LON:AGL) Parsortix system has shown potential to outperform current standards of care for the detection and assessment of prostate cancer.

The biotechnology firm said the results of work undertaken by Queen Mary University of London's Barts Cancer Institute showed that Parsortix had delivered a “dramatically higher performance” in testing for prostate cancer which then yielded a positive tissue sample, or biopsy.

READ: ANGLE’s Parsortix system could help “significantly improve” diagnosis and treatment of lung cancer

The current standard involves a blood test that ANGLE said had high false-positive rates, resulting in unnecessary tissue biopsies which did not contain cancer cells.

However, using Parsortix 93% of 41 positive results did result in cancer cell detection, meaning that if combined with the existing blood test could prevent a “substantial proportion” of unnecessary biopsies without missing clinically significant prostate cancer cases.

The data from the study will be published in the peer-reviewed Journal of Urology.

"This is a major new study from Barts Cancer Institute demonstrating potential for ANGLE's Parsortix system to transform care in early stage diagnosis for the most prevalent cancer type in men”, said ANGLE’s chief executive, Andrew Newland.

“Prostate cancer is a high priority for the company's development once we have concluded our current FDA and verification studies in breast cancer and ovarian cancer.”

Quick facts: ANGLE PLC

Price: 53 GBX

Market: AIM
Market Cap: £91.58 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...


Angle’s Newland reflects on excellent year as cancer patient trials advance

Angle Plc (LON:AGL, OTCMKTS:ANPCY) is poised to revolutionise cancer treatment with its Parsortix system, here we catch up with chief executive Andrew Newland. As Newland explains Parsortix can capture cancer cells from blood, which is very significant for the emerging field of...

on 07/28/2016

2 min read